Previously, our group had cloned 2B4, CS1, and LLT1 and evaluated their expression and function in various cancers including prostate cancer, triple-negative breast cancer, and acute lymphoblastic leukemia (ALL) [20,31,39,40]. This evidence concerns the gene CLEC2D and acute lymphoblastic leukemia.